Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients
NCT00384384
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
End Stage Renal Disease
Interventions
DRUG:
oral 18B Glycyrrhetinic acid versus placebo
Sponsor
Insel Gruppe AG, University Hospital Bern